Top Analyst Pounds the Table on Warrior Met Coal, Inc. (HCC), ZIOPHARM Oncology, Inc. (ZIOP)

A look at its monthly performance shows that Warrior Met Coal, Inc. (NYSE:HCC) has recorded a 3.38% gain over the past 30 days. Over the past 12 months the stock has embarked on a rally that has seen it rise 15.38% and is now up by 1.41% since start of this year. The equity price rose 5.43% this week, a trend that has led to both investors and traders taking note of the stock. Its equity price dipped by -7.28% over the past three months which led to its overall six-month decrease to stand at -7.42%.

Experts from research firms are bullish about the near-term performance of Warrior Met Coal, Inc. with most of them predicting a $31.67 price target on a short-term (12 months) basis. The average price target by the analysts will see a 29.53% rise in the stock and would lead to HCC’s market cap to surge to $1.66B. The stock has been rated an average 2.4, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 10 analysts that track Warrior Met Coal, Inc. (NYSE:HCC) and find out that 6 of them rated it as a Hold. 4 of the 4 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

A look at HCC technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 54.29 point. Its trading volume has added 358283 shares compared to readings over the past three months as it recently exchanged 1232043 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 873760 shares, and this is 1.41 times the normal volume.

The ZIOP stock Stochastic Oscillator (%D) is at 87.46%, which means that it is currently overbought and its prices could dip very soon. The shares P/S ratio stands at 221.12 which compares to the 242.95 recorded by the industry or the 21.76 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 15.3% over the past five years.

Analysts view ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) as a Hold, with 2.8 consensus rating. Reuters surveyed 4 analysts that follow ZIOP and found that 1 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 2 analyst rating it as a Buy or a Strong Buy while 1 analysts advised investors to desist from buying ZIOPHARM Oncology, Inc. (ZIOP) shares or sell it if they already own it.